rlipo-E7m

**rlipo-E7m** is a recombinant lipidated mutant of the human papillomavirus type 16 (HPV16) E7 oncoprotein, biologically linked to a bacterial lipid moiety. It is engineered to lack the natural oncogenic activity of E7 but retains immunogenic epitopes, designed for use as a therapeutic vaccine targeting HPV-associated tumors. The lipidation allows direct activation of dendritic cells via Toll-like receptor 2 (TLR2), resulting in robust Th1-biased immune responses and strong cytotoxic T lymphocyte (CTL) activity against E7-expressing tumor cells. In preclinical models, rlipo-E7m has shown significant anti-tumor efficacy, inducing potent E7-specific CTL responses, promoting tumor regression, and activating the maturation of antigen-presenting cells. The immunostimulatory effect of rlipo-E7m is specifically mediated by TLR2 on dendritic cells and is not due to contaminant endotoxin. Preclinical research has demonstrated its combination efficacy with immune adjuvants (e.g., CpG ODN) and chemotherapeutic agents (e.g., gemcitabine)[1][3].

Other names

recombinant lipidated HPV16 E7 mutantlipo-E7mlipo-E-7mlipo-E 7m